|
Nanobody® Bibliography
High Selectivity
Lauwereys M, Ghahroudi MA, Desmyter A, Kinne J, Hölzer
W, De Genst E, Wyns L, Muyldermans S. Potent enzyme
inhibitors derived from dromedary heavy-chain antibodies.
EMBO J. 1998 Jul 1; 17(13): 3512-20.
Muyldermans S. Single domain camel antibodies:
current status. J Biotechnol.
2001 Jun; 74 (4): 277-302.
Cortez-Retamozo V, Backmann N, Senter PD, Wernery U,
De Baetselier P, Muyldermans S, Revets H. Efficient
cancer therapy with a nanobody-based conjugate.
Cancer Res. 2004 Apr 15; 64 (8): 2853-7.
Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans
S, Conrath K. Single domain antibodies derived
from dromedary lymph node and peripheral blood lymphocytes
sensing conformational variants of prostate-specific
antigen. J Biol Chem. 2004 Dec
10; 279 (50): 51965-72.
Gibbs WW. Nanobodies. Sci Am.
2005 Aug; 293 (2): 78-83.
Huang L, Reekmans G, Saerens D, Friedt JM, Frederix
F, Francis L, Muyldermans S, Campitelli A, Van Hoof
C. Prostate-specific antigen immunosensing based
on mixed self-assembled monolayers, camel antibodies
and colloidal gold enhanced sandwich assays. Biosens
Bioelectron. 2005 Sep 15; 21(3):483-90.
Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer
R, Lenting PJ. A novel nanobody that detects the
gain-of-function phenotype of von Willebrand factor
in ADAMTS13 deficiency and von Willebrand disease type
2B. Blood. 2005 Nov 1; 106 (9):
3035-42.
|
